2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.04 Seribantumab Results in Robust and Durable Responses in NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multi-Center Case Series

P3.12C.04 Seribantumab Results in Robust and Durable Responses in NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multi-Center Case Series

Back to course

Pdf Summary

The document details a study focusing on seribantumab, a monoclonal antibody targeting HER3, used in treating non-small cell lung cancer (NSCLC) patients with NRG1 gene fusions. These fusions are implicated in lung adenocarcinoma oncogenesis, predominantly affecting never-smokers and are linked to poor responses to conventional therapies.<br /><br />According to the Global eNRGy1 registry, patients with NRG1 gene fusions demonstrate limited response rates to standard treatments, showing 15% ORRs to platinum doublet or taxane chemotherapy and 20-25% ORRs to immunotherapy and afatinib, respectively. In contrast, the phase II CRESTONE trial highlights seribantumab's efficacy, reporting a 39% response rate among NSCLC patients with such fusions.<br /><br />The study, involving retrospective analysis across several hospitals, presents detailed case studies of three patients. Each patient showed significant clinical benefits following treatment with seribantumab:<br /><br />1. **Patient 1**, a 43-year-old woman, achieved a partial response sustained for 24 months and eventually had a complete response in the pleura.<br />   <br />2. **Patient 2**, a 70-year-old man, showed a partial response for 17 months after progressing post-immunotherapy.<br /><br />3. **Patient 3**, a 59-year-old woman, initially had a partial response deepening to complete after six months, with continued benefits over 32 months.<br /><br />These cases underscore seribantumab's promise as a treatment for NRG1 fusion-positive lung cancer, providing robust and durable responses where conventional therapies fall short. The results indicate that targeting HER3 can significantly impact progression and survival rates for this specific NSCLC subset, representing a pivotal shift in managing a challenging clinical population.

Asset Subtitle

Chelsea Lau

Meta Tag

Speaker Chelsea Lau

Topic Metastatic NSCLC – Targeted Therapy

Keywords

seribantumab

HER3

non-small cell lung cancer

NSCLC

NRG1 gene fusions

lung adenocarcinoma

CRESTONE trial

monoclonal antibody

oncogenesis

immunotherapy